Proteostasis Ther Cmn (NASDAQ:PTI) shares traded 0.49% up during most recent session to reach at the closing price of $4.14. The stock exchanged hands 1.23 Million shares versus average trading capacity of 1.52 Million shares, yielding a market cap of $120.06 Million. Wall Street analysts covering the stock are projecting that the stock will reach $16 within the next 52-weeks. The mean target projections are based on 3 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Proteostasis Ther Cmn (NASDAQ:PTI) high price target of $25 and with a conservative view have low price target of $8.

RBC Capital “Initiates Coverage On” Proteostasis Ther Cmn (NASDAQ:PTI) in a research note issued to investors on 3/09/18 to Outperform with price target of $11.

Additionally on 4/18/16 Guggenheim “Initiates Coverage on” Proteostasis Ther Cmn (NASDAQ:PTI) to Neutral and on 3/07/16 Leerink Swann “Initiates Coverage on” the stock to Outperform at $13. Furthermore on 3/07/16 RBC Capital “Initiates Coverage on” the stock to Outperform at $20.

On the other hand the company has Relative Strength Index (RSI 14) of 63.25 along with Average True Range (ATR 14) of 0.35, Consequently Proteostasis Ther Cmn (NASDAQ:PTI)’s weekly and monthly volatility is 8.80%, 9.74% respectively. The company’s beta value is at 0.

In terms of Buy, Sell or Hold recommendations, Proteostasis Ther Cmn (NASDAQ:PTI) has analysts’ mean recommendation of 1.8. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Proteostasis Ther Cmn (NASDAQ:PTI)’s minimum EPS for the current quarter is at $-0.72 and can go high up to $-0.61. The consensus mean EPS for the current quarter is at $-0.65 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.38 earnings per share for the same quarter during last year.

Previously Proteostasis Ther Cmn (NASDAQ:PTI) reported $-0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.72 by $0.16. The company posted an earnings surprise of 22.2%.

Proteostasis Ther Cmn (NASDAQ:PTI)’s revenue estimates for the current quarter are $1.42 Million according to 3 number of analysts, for the current quarter the company has high revenue estimates of $1.6 Million in contradiction of low revenue estimates of $1.1 Million. For the current year the company’s revenue estimates are $5.14 Million compared to low analyst estimates of $4.82 Million and high estimates of $5.32 Million according to 3 number of analysts.

Currently Proteostasis Ther Cmn (NASDAQ:PTI)’s shares owned by insiders are 1.3%, whereas shares owned by institutional owners are 72.2%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 45.61%.

Proteostasis Ther Cmn (NASDAQ:PTI) 52-week high price stands at $13.30 and low price stands at $1.41, its price distance from 52-week high is -68.87% while its distance from 52-week low price is 193.62%. The stock hit its 52-week high on 03/28/17, and 52-week low on 11/13/17.

Proteostasis Ther Cmn (NASDAQ:PTI)’s trailing twelve month revenues are $7.8 Million, whereas its price to sales ratio for the same period is 15.39. Its book value per share for the most recent quarter is $1.53 while its price to book ratio for the same period is 2.71, as for as the company’s cash per share for the most recent quarter is $1.49, however its price to cash per share ratio for the same period is 2.78. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.